Literature DB >> 11741835

DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes.

M Ehrlich1, K L Buchanan, F Tsien, G Jiang, B Sun, W Uicker, C M Weemaes, D Smeets, K Sperling, B H Belohradsky, N Tommerup, D E Misek, J M Rouillard, R Kuick, S M Hanash.   

Abstract

ICF (immunodeficiency, centromeric region instability and facial anomalies) is a recessive disease caused by mutations in the DNA methyltransferase 3B gene (DNMT3B). Patients have immunodeficiency, chromosome 1 (Chr1) and Chr16 pericentromeric anomalies in mitogen-stimulated lymphocytes, a small decrease in overall genomic 5-methylcytosine levels and much hypomethylation of Chr1 and Chr16 juxtacentromeric heterochromatin. Microarray expression analysis was done on B-cell lymphoblastoid cell lines (LCLs) from ICF patients with diverse DNMT3B mutations and on control LCLs using oligonucleotide arrays for approximately 5600 different genes, 510 of which showed a lymphoid lineage-restricted expression pattern among several different lineages tested. A set of 32 genes had consistent and significant ICF-specific changes in RNA levels. Half of these genes play a role in immune function. ICF-specific increases in immunoglobulin (Ig) heavy constant mu and delta RNA and cell surface IgM and IgD and decreases in Ig(gamma) and Ig(alpha) RNA and surface IgG and IgA indicate inhibition of the later steps of lymphocyte maturation. ICF-specific increases were seen in RNA for RGS1, a B-cell specific inhibitor of G-protein signaling implicated in negative regulation of B-cell migration, and in RNA for the pro-apoptotic protein kinase C eta gene. ICF-associated decreases were observed in RNAs encoding proteins involved in activation, migration or survival of lymphoid cells, namely, transcription factor negative regulator ID3, the enhancer-binding MEF2C, the iron regulatory transferrin receptor, integrin beta7, the stress protein heme oxygenase and the lymphocyte-specific tumor necrosis factor receptor family members 7 and 17. No differences in promoter methylation were seen between ICF and normal LCLs for three ICF upregulated genes and one downregulated gene by a quantitative methylation assay [combined bisulfite restriction analysis (COBRA)]. Our data suggest that DNMT3B mutations in the ICF syndrome cause lymphogenesis-associated gene dysregulation by indirect effects on gene expression that interfere with normal lymphocyte signaling, maturation and migration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741835     DOI: 10.1093/hmg/10.25.2917

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  34 in total

1.  Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site.

Authors:  Holly Maier; Jeff Colbert; Daniel Fitzsimmons; Dawn R Clark; James Hagman
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

Review 2.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

3.  Selective demethylation and altered gene expression are associated with ICF syndrome in human-induced pluripotent stem cells and mesenchymal stem cells.

Authors:  Kevin Huang; Zhourui Wu; Zhenshan Liu; Ganlu Hu; Juehua Yu; Kai H Chang; Kee-Pyo Kim; Thuc Le; Kym F Faull; Nagesh Rao; Andrew Gennery; Zhigang Xue; Cun-Yu Wang; Matteo Pellegrini; Guoping Fan
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

4.  Identification of a novel leukemic-specific splice variant of DNMT3B and its stability.

Authors:  Prachi Singh; Sarvagalla Sailu; Elango Palchamy; Mohane Selvaraj Coumar; Sudhakar Baluchamy
Journal:  Med Oncol       Date:  2017-07-20       Impact factor: 3.064

5.  A Novel Mutation in a Critical Region for the Methyl Donor Binding in DNMT3B Causes Immunodeficiency, Centromeric Instability, and Facial Anomalies Syndrome (ICF).

Authors:  Erez Rechavi; Atar Lev; Eran Eyal; Ortal Barel; Nitzan Kol; Sarit Farage Barhom; Ben Pode-Shakked; Yair Anikster; Raz Somech; Amos J Simon
Journal:  J Clin Immunol       Date:  2016-10-12       Impact factor: 8.317

6.  Delineation of a Human Mendelian Disorder of the DNA Demethylation Machinery: TET3 Deficiency.

Authors:  David B Beck; Ana Petracovici; Chongsheng He; Hannah W Moore; Raymond J Louie; Muhammad Ansar; Sofia Douzgou; Sivagamy Sithambaram; Trudie Cottrell; Regie Lyn P Santos-Cortez; Eloise J Prijoles; Renee Bend; Boris Keren; Cyril Mignot; Marie-Christine Nougues; Katrin Õunap; Tiia Reimand; Sander Pajusalu; Muhammad Zahid; Muhammad Arif Nadeem Saqib; Julien Buratti; Eleanor G Seaby; Kirsty McWalter; Aida Telegrafi; Dustin Baldridge; Marwan Shinawi; Suzanne M Leal; G Bradley Schaefer; Roger E Stevenson; Siddharth Banka; Roberto Bonasio; Jill A Fahrner
Journal:  Am J Hum Genet       Date:  2020-01-09       Impact factor: 11.025

7.  A p38 MAPK-MEF2C pathway regulates B-cell proliferation.

Authors:  Dustin Khiem; Jason G Cyster; John J Schwarz; Brian L Black
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

8.  TERRA, CpG methylation and telomere heterochromatin: lessons from ICF syndrome cells.

Authors:  Zhong Deng; Amy E Campbell; Paul M Lieberman
Journal:  Cell Cycle       Date:  2010-01-01       Impact factor: 4.534

9.  Altered intra-nuclear organisation of heterochromatin and genes in ICF syndrome.

Authors:  Andrew Jefferson; Stefano Colella; Daniela Moralli; Natalie Wilson; Mohammed Yusuf; Giorgio Gimelli; Jiannis Ragoussis; Emanuela V Volpi
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

10.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.